However, in a pooled analysisfrom the TAXUS Clinical Program involving 3513 patients, no differences wereobserved between PES and BMS in patients with DM regarding rates of death,myocardial infarction (MI), or stent thrombosis (ST) [82], despite lower rates ofTLR over 4 years with DES—a consistent benefit observed in both insulin-treated(IDDM) and non–insulin-treated diabetic (NIDDM) patients. This evidence concerns the gene INS and myocardial infarction.